BMS has done a very competent job marketing Zeposia/ozanimod for MS in a crowded market despite launching during the early days of Covid-19 (they were the third S1PR modulator after Novartis' Gilenya/fingolimod around 2012/2013 and Novartis' Mayzent/siponimod in 2019 and now a fourth one Janssen's Ponvory/ponesimod just approved for MS 2 months ago). All of them priced fairly similarly (80k+/year though actual price after discounts closer to 50K). I believe Zeposia is now the most newly prescribed S1PRM. Both Zeposia and Mayzent are easier to initiate than Gilenya
I would think they would do well as the first approved S1PR modulator for UC, but I don't know that market well as far as pros/cons of competing drugs. Treatment paradigms are very different (MS DMTs are exclusively monotherapy and mild MS is treated similarly to moderate while polytherapy is more common for severe UC with milder patients not needing strong immunomodulators). Getting a good formulary position could be very troublesome due to price. The MS drugs tend to all be about 80-85k/year but UC med's are less and I don't think they can change one price for one indication and a different price for another.
Market Data 
Markets 
AI
